Chardan Capital Initiates Coverage On Immunovant with Buy Rating, Announces $30 Price Target; Names A Top Pick For 2020

Chardan Capital analyst Gbola Amusa initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and a $30 price target.

Benzinga · 01/09/2020 16:19

Chardan Capital analyst Gbola Amusa initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and a $30 price target.